Gilead Sciences Inc. (GILD)
Gilead Sciences, Inc. (GILD) Q4 2024 Earnings Call Transcript
Gilead Sciences, Inc. (NASDAQ:GILD ) Q4 2024 Earnings Conference Call February 11, 2025 4:30 PM ET Company Participants Jacquie Ross - SVP, Treasury & IR Daniel O'Day - Chairman, CEO Johanna Mercier - Chief Commercial Officer Dietmar Berger - Chief Medical Officer Andrew Dickinson - CFO Cindy Perettie - EVP, Kite Conference Call Participants Geoff Meacham - Citigroup Terrence Flynn - Morgan Stanley Tim Anderson - Bank of America Umer Raffat - Evercore ISI Michael Yee - Jefferies Daina Graybosch - Leerink Partners Mohit Bansal - Wells Fargo Brian Abrahams - RBC Capital Markets Tyler Van Buren - TD Cowen Ellie Merle - UBS Courtney Breen - Bernstein Operator Good afternoon, everyone, and welcome to Gilead's Fourth Quarter and Full Year 2024 Earnings Conference Call. My name is Rebecca, and I'll be today's host.
Gilead (GILD) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Gilead (GILD) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Gilead Sciences (GILD) Tops Q4 Earnings and Revenue Estimates
Gilead Sciences (GILD) came out with quarterly earnings of $1.90 per share, beating the Zacks Consensus Estimate of $1.67 per share. This compares to earnings of $1.72 per share a year ago.
Gilead Sciences Beats Q4 EPS Forecast
Gilead Sciences (GILD 0.69%), a major player in the biotechnology sector, reported fourth-quarter and full-year 2024 earnings on Tuesday, Feb. 11, that topped analysts' consensus estimates. Adjusted earnings per share of $1.90 came in well ahead of the estimated $1.74.
Gilead quarterly results beat estimates
Gilead Sciences posted fourth-quarter results that exceeded Wall Street estimates on Tuesday as its HIV drug sales rose 16% and acquisition-related costs fell.
Gilead Sciences: Diversification Strategy Not Derisked Enough Yet
Gilead Sciences: Diversification Strategy Not Derisked Enough Yet
Gilead Sciences to Report Q4 Earnings: Is a Beat in the Cards?
Investors' focus will likely be on GILD's HIV franchise performance and oncology sales when the company reports fourth-quarter 2024 results.
Ahead of Gilead (GILD) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Beyond analysts' top -and-bottom-line estimates for Gilead (GILD), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2024.
Gilead Sciences (GILD) Surpasses Market Returns: Some Facts Worth Knowing
Gilead Sciences (GILD) closed at $99.65 in the latest trading session, marking a +1.69% move from the prior day.
Gilead Sciences (GILD) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
Gilead (GILD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Gilead Sciences (GILD) Rises As Market Takes a Dip: Key Facts
In the most recent trading session, Gilead Sciences (GILD) closed at $98.38, indicating a +1.21% shift from the previous trading day.
Gilead: Strong Sales Growth Remains With Veklury And Beyond
Company sees strong growth in VEKLURY sales, driven by increased Covid-19 hospitalizations, with Q3 2024 sales up 9% to $692 million. LIVDELZI shows promise for long-term growth, with FDA Accelerated Approval for PBC and potential EMA approval in Q1 2025. TRODELVY sales increased by 17% year-over-year, with potential expansion into ES-SCLC and other Trop-2 expressing solid tumors.
